Horseshoe Crab Hemocyte-derived Antimicrobial Polypeptides, Tachystatins, with Sequence Similarity to Spider Neurotoxins

(Received for publication, March 16, 1999, and in revised form, May 18, 1999)

Tsukasa Osaki, Miyuki Omotezako, Ranko Nagayama, Michimasa Hirata, Sadaaki Iwanaga, Jiro Kasahara, Junji Hattori, Isao Ito, Hiroyuki Sugiyama, and Shun-ichi Kawabata

From the Department of Molecular Biology, Graduate School of Medical Science, Kyushu University, Fukuoka 812-8581, and the Department of Bacteriology, Iwate Medical University, Morioka 020-8505, Japan

Antimicrobial peptides, named tachystatins A, B, and C, were identified from hemocytes of the horseshoe crab Tachypleus tridentatus. Tachystatins exhibited a broad spectrum of antimicrobial activity against Gram-negative and Gram-positive bacteria and fungi. Of these tachystatins, tachystatin C was most effective. Tachystatin A is homologous to tachystatin B, but tachystatin C has no significant sequence similarity to tachystatins A and B. Tachystatins A and B showed sequence similarity to ω-agatoxin-IVA of funnel web spider venom, a potent blocker of voltage-dependent calcium channels. However, they exhibited no blocking activity of the P-type calcium channel in rat Purkinje cells. Tachystatin C also showed sequence similarity to several insecticidal neurotoxins of spider venoms. Tachystatins A, B, and C bound significantly to chitin. A causal relationship was observed between chitin binding activity and antifungal activity. Tachystatins caused morphological changes against a budding yeast, and tachystatin C had a strong cell lysis activity. The septum between mother cell and bud, a chitin-rich region, was stained by fluorescein-labeled tachystatin C, suggesting that the primary recognizing substance on the cell wall is chitin. As horseshoe crab is a close relative of the spider, tachystatins and spider neurotoxins may have evolved from a common ancestral peptide, with adaptive functions.

Immunity to infectious agents is mediated by two general systems, innate and acquired. Innate immunity is phylogenetically older than acquired immunity, and a certain form of innate immunity is present in all multicellular organisms. Insects respond to septic injury by the rapid and transient synthesis of defense molecules, as an acute phase reaction (1, 2). On the other hand, major defense molecules of horseshoe crab are constitutively present in hemolymph plasma and hemocytes (3–8). The hemolymph contains granular hemocytes composed of two populations of secretory granules, named large and small granules (9). These hemocytes have two populations of secretory granules, named large and small granules (9). These hemocytes are highly sensitive to lipopolysaccharides, which are major outer membrane components of Gram-negative bacteria. The defense molecules stored in both granules are secreted by exocytosis after stimulation with lipopolysaccharides. This response is important for the host defense related to engulfing and killing invading microbes in addition to preventing the leakage of hemolymph. Large granules contain all the clotting factors essential for hemolymph coagulation in addition to various protease inhibitors (10–13) and lectins (14–17). On the other hand, small granules contain mainly antimicrobial substances such as tachyplesin (18) and several cysteine-rich peptides of molecular masses of 6–8 kDa, but functions are unknown (19). Two components of small granules, big defensin and tachycin, have been functionally and structurally characterized (20, 21).

Horseshoe crab hemocyte-derived antimicrobial peptides named tachystatins A, B, and C, with structural similarity to spider neurotoxins, were newly purified and biochemically characterized. Unlike big defensin and tachycin previously identified, these tachystatins have a characteristic chitin binding ability in addition to a strong antimicrobial activity against Gram-negative and Gram-positive bacteria and fungi.

EXPERIMENTAL PROCEDURES

Materials—Hemocyte debris from the Japanese horseshoe crab Tachypleus tridentatus was prepared as described (22). Tachyplesin (18), big defensin (20), and tachycin (21) were purified as described. Sources of materials used were as follows; Sephadex G-50 fine and S-Sepharose fast flow from Amersham Pharmacia Biotech, chitin from Seikagaku Corp., Tokyo, wheat germ agglutinin and lysyl endopeptidase from Wako Pure Chemical Industries, Ltd., Tokyo, endoproteinase Asp-N from Roche Molecular Biochemicals, trypsin and chymotrypsin from Worthington Biochemical Co., Freehold, NJ, basal medium Eagle, human transferrin, and bovine insulin from Life Technologies, Inc., bovine serum albumin, aprotinin, l-thyroxin, DNase I, and calcofluor white from Sigma, a sheep blood sample from Nippon Bio-Test Laboratories, Tokyo, and ω-agatoxin IVA from Peptide Institute Inc., Osaka.

Antimicrobial Activity and Morphological Effects of Tachystatins on Bacteria and Fungi—Antimicrobial activity was assayed as described (20) using Escherichia coli (clinical isolate), Staphylococcus aureus, Candida albicans, and Pichia pastoris. For microscopic analysis, P. pastoris was collected by centrifugation and washed twice with 10 mM sodium phosphate buffer, pH 7.0. The fungal suspension, 10 μl, was mixed with 10 μl of a 2-fold serial-diluted tachystatins A, B, or C with the same buffer and placed in each well of a 12-well slide glass and incubated at 30 °C for 2 h. Morphological changes were assessed using an Olympus microscope, model BX 50.

For fluorescence microscopic analysis, tachystatin C was labeled using an Alexa-488 protein labeling kit (Molecular Probes, Inc., Eugene, OR) and a protocol provided by the manufacturer. The suspension of P. pastoris was mixed with the labeled tachystatin C (a final concentration of 0.18 mg/ml) or the fluorescence ligand coupled with bovine serum albumin (a final concentration of 0.5 mg/ml) as a negative control.
control and incubated at 22 °C for 15 min. Under these conditions, tachystatin C caused little cell lysis of *P. pastoris*. A chitin binding fluorescence agent, calciofluor (a final concentration of 0.1 mg/ml) was also used for positive staining of the cell wall. Fluorescence microscopic images were taken using an Olympus fluorescence microscope, model BX-FLA.

**Chitin Binding**—Chitin (0.5 mg) was mixed with antimicrobial substances in 100 μl of 20 mM Tris-HCl buffer, pH 7.5, containing 0.15 M NaCl and 2 mM CaCl₂, then incubated at room temperature for 15 min and centrifuged at 15,000 rpm for 2 min. The supernatant was removed, and the precipitate was washed with 1 ml of the same buffer and eluted with 100 μl of 0.1 M HCl. The concentrations of the bound form were determined using the eluted substance as a standard.

**Hemolytic Activity**—Antimicrobial substances dissolved in 0.5 ml of 50 mM Tris-HCl, pH 7.5, containing 0.15 M NaCl were mixed with the same volume of sheep erythrocytes in the same buffer (final 1%, v/v) and incubated at 37 °C. An aliquot was taken at 1-h interval and centrifuged to obtain supernatant. The hemolytic activity was determined by measuring the absorbance at 546 nm as a result of hemoglobin released from erythrocytes and compared with complete lysis (100% hemolysis) obtained by adding deionized water instead of saline.

**Proteolytic Digestion**—The samples were treated and S-alkylated with 4-vinylpyridine as described (23). The S-alkylated tachystatin A was digested with trypsin or chymotrypsin (E/S = 1/25, w/w) in 0.1 M NH₄HCO₃ containing 2 M urea at 37 °C for 12 h. The S-alkylated tachystatin B was digested with endoproteinase Asp-N (E/S = 1/25, w/w) in 20 mM Tris-HCl, pH 7.5, containing 2 mM urea at 37 °C for 12 h. The S-alkylated tachystatin C was digested with lyso endopeptidase (activator/substrate = 1/25, w/w) in 0.1 M NH₄HCO₃ containing 2 M urea at 37 °C for 12 h. The resulting peptides were separated by reverse-phase HPLC using a Cosmosil 5C18 MS (2.0 × 150 mm, Nacalai Tesque Inc., Kyoto) or a Bondasphere 5C8 (2.1 × 150 mm, Waters, Millipore, Milford, MA) column with a linear gradient of 0–48% acetonitrile in 0.06% trifluoroacetic acid for 90 min at a flow rate of 0.2 ml/min. The effluent was monitored at 210 nm.

**Amino Acid and Sequence Analyses**—Amino acid analysis was performed on a Waters PICO-.TAG system. Protein concentrations for determining extinction coefficients of tachystatins were calculated from the amino acid mass/μmol. An internal standard, norleucine, was added to the protein hydrolysates to allow for correction for losses. Amino acid sequence analysis was carried out using an Applied Biosystems 477A or 473A gas phase sequencer.

**ESI-Mass Spectrometry**—The ESI-mass spectrometry spectra were obtained using a JMS-HX/HX110A double-focusing mass spectrometer (JEOL, Tokyo) equipped with an ESI ion source (Analytical of Branford, Branford, CT). Experimental details were as described (24).

**Tachystatin A-specific DNA Probe and Screening of cDNA Library**—The degenerate nucleotide sequences of the primers used for polymerase chain reaction were based on the amino acid sequences of QGFNCV (residues 7–12) and YFPGST (residues 32–37) of tachystatin A. Sense and antisense nucleotides were synthesized with an Applied Biosystems 477A or 473A gas phase sequencer.

**Computer-assisted homology search** was made using the Internet BLAST Search of National Center for Biotechnology Information (NCBI).

**Electrophysiology**—Cultivation of Purkinje cells and the electrophysiological experiments were done as described (27). Cerebella were dissected from rat fetuses around embryonic days 18 to 20, treated with 1% trypsin, and dispersed in serum-free defined medium (28) by gentle pipetting, then plated on 10-mm round glass coverslips coated with poly-l-lysine. Purkinje cells after the days 25 to 35 in vitro were voltage-clamped at −80 mV and depolarized periodically to −10 mV for 60 ms to record Ca²⁺ currents using the whole-cell patch clamp recording system (27). The compositions of external and patch internal solutions were as follows: external solution, 10 mM Hepes-NaOH, pH 7.35, containing 150 mM NaCl, 5 mM KCl, 1 mM MgCl₂, 2 mM CaCl₂, 10 mM glucose, 0.003 mM tetrodotoxin, 10 mM tetraethylammonium chloride, and 1 mM 4-aminopyridine; patch internal solution, 10 mM Hepes-CaOH, pH 7.35, containing 140 mM CsCl, 1 mM MgATP, 2 mM MgGTP, and 0.4 mM NaGTP. α-Agatoxin IVA and tachystatins A and B were dissolved in deionized water and diluted with external solution just before use.

**RESULTS**

**Purification of Three Types of Tachystatins**—The hemocyte debris (36 g, wet weight) was extracted twice by homogenizing with 200 ml of 30% acetic acid, and the supernatant obtained by centrifugation at 14,000 rpm for 15 min was lyophilized. The dried material was dissolved in 50 ml of 10% acetic acid and applied to a Sephadex G-50 column (3.6 × 110 cm). Fractions indicated by a solid bar were collected. B, ion exchange column chromatography on an S-Sepharose fast flow column (2 × 32 cm). A broken line indicates the concentration of NaCl. C, SDS-PAGE of purified tachystatins A, B, and C under reducing conditions.
Horseshoe Crab-derived Antimicrobial Peptides

**TABLE I**

| Amino acid residues | pI | IC50$_{50}$ | E. coli | S. aureus | C. albicans | P. pastoris |
|---------------------|----|------------|---------|-----------|-------------|-------------|
| Tachystatin A       | 44 | 11.8      | 25      | 4.2       | 3.0         | 0.5         |
| Tachystatin B       | 42 | 12.0      | NF      | 7.4       | 3.0         | 0.1         |
| Tachystatin C       | 41 | 11.9      | 1.2     | 0.8       | 0.9         | 0.3         |
| Tachylespin         | 17 | 12.3      | <2.5    | 0.3       | 0.2         | 0.1         |
| Big defensin        | 79 | 10.6      | 2.5     | <2.5      | 20          | 42          |
| Tachystatin C       | 73 | 10.1      | 33      | 56        | 52          | 41          |

* Each pI value of the peptides was calculated from the amino acid compositions (46).

Antimicrobial Activity and Morphological Effects of Tachystatins on Bacteria and Fungi—The 50% inhibitory concentrations (IC$_{50}$) of tachystatins for growth of various bacteria and fungi were determined, as summarized in Table I. Tachystatins A and B exhibited stronger antimicrobial activity against the Gram-positive bacteria (S. aureus) and fungi (C. albicans and P. pastoris) than Gram-negative bacteria (E. coli). Tachystatin B was inactive against E. coli up to 100 µg/ml. In contrast, tachystatin C showed strong activity against E. coli with an IC$_{50}$ value of 1.2 µg/ml. Tachystatin C was also very active against S. aureus, C. albicans, and P. pastoris, with the equivalent potency of IC$_{50}$ values.

Morphological changes of fungi by tachystatins were observed using a budding yeast P. pastoris (Fig. 3). In the presence of tachystatin C at 0.1 µg/ml, one-third of IC$_{50}$, P. pastoris shrank, and the diameter was reduced to about one-half (Fig. 3, A and B). At 3 µg/ml, a 10-fold higher concentration of IC$_{50}$, tachystatin C clearly caused cell lysis (Fig. 3C).

Chitin Binding Activity of Tachystatins—To compare quantitatively the chitin binding ability, different amounts of the horseshoe crab antimicrobial components were mixed with the constant amount of chitin, and the amounts bound were quantitated. Chitin binding activity was expressed, as the half-maximum concentration required for reaching a plateau of chitin binding. A progression curve of tachystatin C bound to chitin is shown in Fig. 4, and parameters of the chitin binding activities are summarized in Table II. The three tachystatins bound to chitin at the half-maximum concentrations of 4.3–8.4 µM, equivalent to those obtained for tachylespin and a plant chitin binding lectin, wheat germ agglutinin (29, 30). These data indicate that tachystatins also belong to the family of chitin binding antimicrobial substances.

Visualization of Chitin Binding Activity—The broad spectrum of antimicrobial activity and chitin binding activity of tachystatins suggested that tachystatins recognize bacterial cell wall components. The cell wall of budding yeasts contains several polysaccharides, such as mannan, glucan, and chitin. During budding in the cell cycle, chitin has been identified mainly in a primary septum at the constriction between mother cell and budding daughter cell (31). This region can be visualized by a fluorescent brightener, calcofluor (32, 33). When P. pastoris was treated with calcofluor, the septum region between mother cell and bud was clearly stained (Fig. 5B). To visualize tachystatins bound to the cell wall, tachystatin C was fluorescence labeled by Alexa 488. The labeled tachystatin C was mixed with P. pastoris, and photomicroscopy was done as described under “Experimental Procedures.” The labeled tachystatin C was localized at the P. pastoris envelope and seems to be concentrated at the septum region (Fig. 5A). The cell wall was not stained by fluorescence-labeled bovine serum albumin, used as a control (data not shown).
Hemolytic Activity of Tachystatins—

Because tachystatin C could lyse *P. pastoris* cells, effects of three types of tachystatins on sheep erythrocytes were investigated and compared with findings in other horseshoe crab antimicrobial substances. Tachystatin C caused hemolysis in time- and dose-dependent manners, but tachystatins A and B and the antimicrobial substances, including tachyplesin, big defensin, and tachycitin, had little or no effect on the erythrocytes under the same conditions (Figs. 6, A and B). Several hemolysins and hemolytic lectins form ion-permeable pores in erythrocyte membranes, and their hemolytic activities are protected by the addition of polyethylene glycols or dextrans, an osmotic protection (34). To test whether or not the hemolytic activity of tachystatin C is due to the formation of ion-permeable pores on the plasma membranes, osmotic protection assay was done. Sheep erythrocytes were incubated with tachystatin C in the presence of several protectants with different molecular sizes. The hemolysis was inhibited strongly as the molecular sizes of polyethylene glycols or dextrans increased; polyethylene glycol 600 (molecular diameter ~5.16 nm) and polyethylene glycol 1,540 (2.4 nm) afforded little or no protection against lysis, whereas dextran 4 (3.5 nm) and polyethylene glycol 4,000 (3.8 nm) gave 88 and 95% protection against hemolysis, respectively (Fig. 6C). These results indicate the presence of ion-permeable pores on the erythrocyte membranes with a diameter of about 3.5 nm.

**TABLE II**

| Chitin binding activities of the horseshoe crab antimicrobial peptides |
|-------------|
| Concentration required for 50% binding (μM) |
| Tachystatin A | 8.4 |
| Tachystatin B | 4.3 |
| Tachystatin C | 5.2 |
| Tachyplesin | 6.6 |
| Big defensin | 25.4 |
| Tachycitin | 19.5 |
| Wheat germ agglutinin* | 9.0 |

* Wheat germ agglutinin was calculated as the dimer (*M*/*, 37,510).

Peptide and Nucleotide Sequencing of Three Types of Tachystatins—

The amino acid sequences of tachystatins A1, A2, B1, B2, and C were determined by NH₂-terminal sequence analyses of the S-pyridylethylated tachystatins and their peptide fragments produced by proteolytic digests (Fig. 7). Tachystatins A1 and A2 could not be separated by reverse-phase...
HPLC, but the amino acid sequence analysis of tachystatin A containing A1 and A2 established the first 42 residues, indicating the amino acid difference between the isoform is located at the COOH-terminal region. Furthermore, the chymotryptic digest of tachystatin A yielded two kinds of the COOH-terminal peptides, C9F containing Phe at the COOH terminus and C5Y containing Tyr at the COOH terminus, indicating that two peptides are derived from tachystatin A1 and tachystatin A2, respectively. The theoretical masses of tachystatins A1 (5039.8) and A2 (5055.8) from the primary structures were consistent with those obtained by ESI-mass spectrometry (Fig. 2A). Amino acid analyses indicated that the compositions of the tachystatins A, B, and C were closely consistent with the sum of their sequences (Table III).

A nucleotide sequence was also determined to obtain information on a precursor form of tachystatins, using a probe for tachystatin A as described under “Experimental Procedures.” A positive clone with the longest insert was sequenced. The cDNA contained 545 base pairs starting with the ATG codon for an initiation Met at nucleotide position 55 and the stop codon at position 256 followed by a poly(A) tail at position 509 (Fig. 8). An open reading frame coded for an NH2-terminal signal sequence of 23 residues and a mature tachystatin A2. The precursor contained no propeptide with an Arg-Xaa-Lys/Arg-Arg motif at the cleavage site found in big defensin (35). Moreover, there was no COOH-terminal extension peptides found in tachyplesin (36) and tachycitin (21).

Sequence Similarity—Tachystatin A1 and A2 had 42% sequence identity with tachystatin B1 and B2, respectively (Fig. 9A). Tachystatin C, however, exhibited no significant sequence similarity to tachystatins A and B. Homology search revealed interesting sequence identity (22%) of tachystatins A and B with ω-agatoxin-IVA (Fig. 9A). ω-Agatoxin-IVA, a neurotoxin isolated from the venom of the funnel web spider (Agelenopsis aperta), is a potent blocker of voltage-dependent P-type Ca2+ channels in mammals (37). On the other hand, tachystatin C had 30–33% sequence identity to insecticidal peptides isolated from spider venoms, such as ω-agatoxin II from A. aperta (38), aptotoxin VII from Aptostichus schlingeri (39), and curtatoxins II and III from Hololena curta (40) (Fig. 9B). ω-Agatoxin II is a neurotoxin that modifies the kinetics of voltage-dependent Na+ channels in insects (41).

Effects of Tachystatins on Ca2+ Channel Currents—To determine if tachystatins block Ca2+ channel activity, voltage clamp recording was done using cultured rat cerebellar Purkinje cells. Depolarization of the Purkinje cells resulted in the inward currents (data not shown). When the external solution replaced the Ca2+-free solution, the currents completely disappeared, and these currents were also blocked almost completely with 75 nM ω-agatoxin IVA. The relative amplitudes were 0% ± 0%...
Horseshoe Crab-derived Antimicrobial Peptides

A

| Tachystatin A1 | KEECDQGEFDCVHRGTPFCCACRCLCFNPTVNSQCVNSCQY |
| Tachystatin B1 | KEECDQGEFDCVHRGTPFCCACRCLCFNPTVNSQCVNSCQY |
| α-Agotatin IV | KEECDQGEFDCVHRGTPFCCACRCLCFNPTVNSQCVNSCQY |

| Tachystatin C | GDESMRFPCPCTYYKCTWNPCCACILQCK-----AGAARP |
| μ-Agotatin II | CECTYKPCACAGWFCOCOOGCSCSRYQPCAPSE |
| Curtastatin II | ALQDCGDKQPCACAGWFCOCOOGCSCSRYQPCAPSE |
| Curtastatin III | ALQDCGDKQPCACAGWFCOCOOGCSCSRYQPCAPSE |

Fig. 9. Sequence comparisons of tachystatins and neurotoxins from spider venoms. Consensus amino acid residues are indicated in bold small capital letters. The conserved cysteine residues are indicated in bold large capital letters. A, alignment of the amino acid sequence of tachystatin A1 and B1 with α-agatoxin-IVA. B, alignment of the amino acid sequence of tachystatin C with those of insecticidal peptides from venom of the spiders.

(mean ± S.E.) by Ca^{2+}-free solution and 5% ± 3.5% by 75 nM μ-agatoxin IVA, respectively. These results clearly indicate that the currents are P-type Ca^{2+} currents. In contrast, tachystatins A and B had no apparent effects on P-type Ca^{2+} currents. Relative amplitudes were 96% ± 2.4% by 100 nM tachystatin B and 95% ± 2.2% by 300 nM tachystatin A.

Discussion

Antimicrobial peptides named tachystatins A, B, and C were newly identified from hemocytes of the Japanese horseshoe crab T. tridentatus. Furthermore, their isoforms with amino acid replacements for tachystatins A, tachystatins A1 and A2, tachystatin B, and tachystatins B1 and B2 were identified. Tachystatins A (A1 and A2), B (B1 and B2), and C consist of a total 44, 42, and 41 amino acid residues, respectively. The sequence identity between tachystatins A and B is 40%. Tachystatin C showed no significant sequence similarity to tachystatins A and B.

A homology search revealed that tachystatins A and B show sequence similarity to α-agatoxin-IVA of funnel web spider (A. aperta) venom, a potent blocker of voltage-dependent calcium channels. Tachystatin C also shows sequence similarity to those of insecticidal neurotoxins isolated from spider venoms, μ-agatoxin,aptotoxin VII, and curatotoxins II and III. However, tachystatins A and B exhibited no blocking activity of the P-type calcium channel in rat Purkinje neuron. Kim et al. (42) reported that the removal of eight amino acid residues from the COOH-terminal region of α-agatoxin IVA led to a marked reduction in channel-blocking activity, thereby indicating the importance of this region for expressing channel-blocking activity. The hydrophobic COOH-terminal extension found in α-agatoxin IVA is missing from the sequences of tachystatins, and this may explain the lack of blocking activity of tachystatins for the ion channel. Antimicrobial peptides from scorpion blood also have sequence similarity to several neurotoxins, which are ion channel blockers (43). The horseshoe crab is a close relative of spiders and scorpions, all of which belong to Chelicerata. Therefore, these tachystatins and spider neurotoxins may have evolved from a common ancestral peptide, with adaptive functions.

Tachystatin C but not tachystatins A and B exhibits hemolytic activity. Moreover, osmotic protection assays suggest that tachystatin C forms non-permeable pores with a diameter of about 3.5 nm on the membranes (Fig. 6). Several proteins and peptides with cytolytic properties possess a common sequence feature of a cationic site flanked by a hydrophobic surface (44). α-Agotatin IVA (42) and μ-agatoxin (45) consist of a triple-stranded β-sheet. If the three kinds of tachystatins have a common structural motif, the COOH-terminal part of tachystatin C appears to form an amphiphilic β-sheet, but the corresponding β-sheets of tachystatins A and B do not have the amphiphilic character (Fig. 10). Therefore, the amphiphilic COOH-terminal region of tachystatin C may have an important role in hemolytic activity and cell lysis of P. pastoris.

Tachystatins have a broad spectrum of antimicrobial activity against Gram-negative and Gram-positive bacteria and fungi. Among them, tachystatin C is the most effective with the same potency against these microorganisms (Table I). Tachystatins, therefore, could recognize different types of cell wall components, such as lipopolysaccharides of Gram-negative bacteria, lipoteichoic acids of Gram-positive bacteria, in addition to mannann, β-glucan, or chitin of fungi. Cell wall binding activity of tachystatin C was visualized on a budding yeast P. pastoris using the fluorescence-labeled tachystatin C. The septum region between mother cell and bud, a chitin-rich site of the yeast, was strongly stained. Thus, the primary recognizing substance on the cell wall of fungi is likely to be chitin. Based on these results, there appears to be a causal relationship between chitin binding activity and antifungal activity, since big defensin and tachycin with lower chitin binding affinity have one or two orders higher IC_{50} values for fungi than those of tachystatins and tachyplesin with higher chitin binding activity (Tables I and II).

Interestingly, the small granule-derived antimicrobial substances so far identified, including tachyplesin, big defensin, tachycin (21), and tachystatin A, all bind to chitin. On the other hand, horseshoe crab lectins found in the large granules of hemocytes, named tachylectins 1–4, have no apparent binding ability to chitin (data not shown). Thus, the chitin binding property may be a common feature of the small granular components. Chitin is a component of the cell wall of fungi, and it is also the major structural component of arthropod exoskeletons. The antimicrobial substances released from hemocytes probably recognize chitin exposed at the site of a lesion, and they appear to serve not only as antibacterial defense molecules against invading microbes but also in wound healing, which may stimulate and accelerate biosynthesis of chitin at sites of injury.

Acknowledgments—We express our thanks to Drs. T. Takao and Y. Shimonishi (the Institute for Protein Research, Osaka University) for mass analysis, W. Kamada for technical assistance with peptide sequencing and amino acid analyses, and M. Ohara for helpful comments on this manuscript.

References

1. Hoffmann, J. A., Heru, C., and Reichhart, J.-M. (1993) FEBS Lett. 325, 63–66
2. Hultmark, D. (1993) Trends Genet. 9, 178–183
3. Iwanaga, S., Miyata, T., Tokunaga, F., and Muta, T. (1992) Thromb. Res. 68,
Horseshoe Crab-derived Antimicrobial Peptides

1. Iwanaga, S. (1999) J. Biol. Chem. 274, 1561–1574
23. Charbonneau, H. (1989) in *A Practical Guide to Protein and Peptide Purification for Microsequencing* (Matudaira, P. T., ed) pp. 15–30, Academic Press Inc., San Diego, CA

24. Shimizu, T., Takao, T., Horumi, K., Nunomura, K., Ohta, S., Shimonoishi, Y., and Ikegami, S. (1997) *Biochemistry* 36, 12071–12079

25. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

26. Laemmli, U. K. (1970) *Nature* 227, 680–685

27. Kasahara, J., and Sugiyama, H. (1998) *Neurosci. Lett.* 247, 139–142

28. Fischer, G. (1982) *Neurosci. Lett.* 28, 325–329

29. Lotan, R., and Sharon, N. (1973) *Biochem. Biophys. Res. Commun.* 55, 1340–1346

30. Privat, J. P., Delmotte, F., Miallonier, G., Bouchard, P., and Monsigny, M. (1974) *Eur. J. Biochem.* 47, 5–14

31. Cabib, E., and Roberts, R. (1982) *Annu. Rev. Biochem.* 51, 763–793

32. Elorza, M. V., Rico, H., and Sentandreu, R. (1983) *J. Gen. Microbiol.* 113, 119–125

33. Roncero, C., and Durán, A. (1985) *J. Bacteriol.* 165, 1180–1185

34. Scherrer, R., and Gerhardt, P. (1971) *J. Bacteriol.* 107, 718–735

35. Saito, T., Kawabata, S., Saito, T., Takeda, K., and Iwanaga, S. (1997) *J. Biol. Chem.* 278, 289–292

36. Shigenaga, T., Muta, T., Toh, Y., and Iwanaga, S. (1990) *J. Biol. Chem.* 265, 21350–21354

37. Mintz, I. M., Venema, V. J., Swiderek, K. M., Lee, T. D., Bean, B. P., and Adams, M. E. (1992) *Nature* 355, 827–829

38. Skinner, W. S., Adams, M. E., Quistad, G. B., Katoaka, H., Cesarin, B. J., Enderlin, F. E., and Schooley, D. A. (1989) *J. Biol. Chem.* 264, 2150–2155

39. Skinner, W. S., Dennis, P. A., Li, J. P., and Quistad, G. B. (1992) *Toxicol. Sci.* 30, 1043–1050

40. Stapleton, A., Blankenship, D. T., Ackermann, B. L., Chen, T. M., Gorder, G. W., Manley, G. D., Palfreyman, M. G., Coutant, J. E., and Cardin, A. D. (1990) *J. Biol. Chem.* 265, 2054–2059

41. Adams, M. E., Herold, E. E., and Venema, V. J. (1989) *J. Comp. Physiol. A Sens. Neural. Behav. Physiol.* 164, 333–342

42. Kim, J. I., Komichi, S., Iwai, H., Kano, T., Geuda, H., Shimada, I., Sato, K., and Arata, Y. (1995) *J. Mol. Biol.* 250, 659–671

43. Ehret-Sabatier, L., Loew, D., Goyffon, M., Fehlbaum, P., Hoffmann, J. A., Van Dorselaer, A., and Bulet, P. (1996) *J. Biol. Chem.* 271, 29537–29544

44. Kini, R. M., and Herbert, J. E. (1989) *Int. J. Pept. Protein Res.* 34, 277–286

45. Omebinski, D. O., Holub, K. E., Adams, M. E., and Reily, M. D. (1996) *Biochemistry* 35, 2836–2844

46. Skoog, B., and Wichman A. (1986) *Trends Anal. Chem.* 5, 82–83